ClinicalTrials.gg
CompletedNCT06465186Updated Sep 21, 2026

A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)

A Phase 2 interventional study of Efinopegdutide and Placebo in Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis and NAFLD, sponsored by Merck Sharp & Dohme LLC. Completed at 68 sites in 11 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.

Enrollment
7th of 10
85 · median 113
Started
2024
with 1 other
Phase 2
7 of 11
none open now
Registered
10th of 11
by date

Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 7 in phase 2, and was the 10th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc as a file.
02

Study summary

Researchers are looking for ways to treat a type of liver disease caused by elevated liver fat, called metabolic dysfunction-associated steatohepatitis (MASH). MASH was formerly called non-alcoholic steatohepatitis (NASH). Researchers want to learn if a study medicine called efinopegdutide can treat MASH.The goals of this study are to learn:

  • If efinopegdutide can lower the amount of fat, inflammation, and scarring (fibrosis) in the liver
  • About the safety of efinopegdutide and how well people tolerate it
03

Conditions studied

  • Non-alcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis
  • NAFLD
  • Metabolic Dysfunction-associated Steatotic Liver Disease
  • Metabolic Dysfunction-associated Steatohepatitis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH)
  • Has either type 2 diabetes that is controlled by diet or medication, or does not have type 2 diabetes

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has history of a liver disease other than MASH, for example, or C, drug-induced liver disease, or liver disease
  • Has history of type 1 diabetes
  • Had a bariatric surgical procedure less than 5 years before entry into the study
  • History of pancreatitis
  • Major illnesses like recent (within 6 months of study entry) episodes of heart problems, such as congestive heart failure, unstable angina, heart attack, stroke, or mini-stroke
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Efinopegdutide

    Participants will start efinopegdutide once a week at the lowest dose level. Then, the dose level will go up every month for three months until they are getting the highest dose level. Efinopegdutide is given as an injection under the skin (subcutaneous injection) for 28 weeks.

    Combination Product: Efinopegdutide

  • Placebo comparator
    Placebo

    Participants will receive placebo once a week. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine. Placebo is given as an injection under the skin (subcutaneous injection) for 28 weeks.

    Combination Product: Placebo

Interventions

  • Combination productEfinopegdutide

    Efinopegdutide is given as a subcutaneous injection using a single-use prefilled syringe, once per week for 28 weeks

    Also known as: MK-6024

  • Combination productPlacebo

    Placebo is given as a subcutaneous injection using a single-use prefilled syringe once per week for 28 weeks.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Liver Fat Content (LFC) at Week 28

    Researchers will measure the change in the amount of fat in the liver using magnetic resonance imaging (MRI) after about 7 months of treatment. The change in MRI-Estimated proton density fat fraction (PDFF) will be measured from baseline to 28 weeks.

    Time frame: Baseline and 28 weeks

  2. Percentage of Participants Who Experienced an Adverse Event (AE)

    An AE is a health problem that happens or worsens during the study

    Time frame: Up to approximately 36 weeks

  3. Percentage of Participants Discontinuing Study Medication Due to an AE

    An AE is a health problem that happens or worsens during a study. The percentage of participants who stop study treatment due to an AE will be reported.

    Time frame: Up to approximately 28 weeks

Secondary outcomes

  1. Change from Baseline in Iron-corrected T1 (cT1) at Week 28

    Researchers will measure the change in liver inflammation and scarring (fibrosis) after about 7 months of treatment. MRI measurement of cT1 mapping will be used to indicate the amount of liver inflammation and fibrosis. The change in cT1 mapping from baseline to 28 weeks will be presented.

    Time frame: Baseline and up to 28 Weeks

  2. Change from Baseline in Enhanced Liver Fibrosis (ELF) score at Week 28

    Researchers will measure the change in liver scarring using biomarkers. Biomarkers are substances measured in blood that show normal or abnormal activity taking place in the liver. ELF is calculated using 3 markers of hepatic extracellular matrix turnover to generate a unitless numerical score. The change from baseline in ELF up to 28 weeks will be reported.

    Time frame: Baseline and up to 28 weeks

  3. Change from Baseline in Propeptide of Type III Collagen (Pro-C3) at Week 28

    Researchers will measure the change in liver scarring using biomarkers. Pro-C3 is measured in serum; Increasing levels indicate worsening of fibrosis activity. The change in Pro-C3 from baseline to 28 weeks will be reported.

    Time frame: Baseline and up to 28 weeks

  4. Change from Baseline in Fibrosis-4 index (FIB-4) at Week 28

    Researchers will measure the change in liver scarring using biomarkers. FIB-4 index is calculated using the participant's age and 3 serum markers (alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], and platelet count). The change from baseline in FIB-4 after 28 weeks will be reported.

    Time frame: Baseline and up to 28 weeks

  5. Change from Baseline in Liver Stiffness Measurement (LSM) Assessed by Vibration-controlled Transient Elastography (VCTE) at week 28

    Researchers will measure the change in liver scarring using ultrasound. LSM is measured using VCTE. The change from baseline in LSM after 28 weeks will be reported.

    Time frame: Baseline and up to 28 weeks

  6. Percent Change from Baseline in Body Weight at Week 28

    Body weight will be measured using a standardized, digital scale. The percent change from baseline in body weight after 28 weeks will be reported

    Time frame: Baseline and up to approximately 28 weeks

07

Study locations

68 sites
  • The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0149)
    Chandler, Arizona 85224, United States
  • Arizona Clinical Trials ( Site 0158)
    Flagstaff, Arizona 86001, United States
  • The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0120)
    Peoria, Arizona 85381, United States
  • The Institute for Liver Health II dba Arizona Liver Health-Tucson ( Site 0111)
    Tucson, Arizona 85712, United States
  • California Liver Research Institute ( Site 0113)
    Pasadena, California 91105, United States
  • Acclaim Clinical Research ( Site 0137)
    San Diego, California 92120, United States
  • Velocity Clinical Research, Panorama City ( Site 0124)
    Van Nuys, California 91405, United States
  • Rocky Mountain Gastroenterology ( Site 0127)
    Littleton, Colorado 80120, United States
  • Synergy Healthcare ( Site 0118)
    Bradenton, Florida 34209, United States
  • Homestead Associates in Research, Inc. ( Site 0139)
    Homestead, Florida 33033, United States
  • Florida Research Institute ( Site 0116)
    Lakewood Rch, Florida 34211, United States
  • Floridian Clinical Research, LLC ( Site 0109)
    Miami Lakes, Florida 33016, United States
  • Southeast Clinical Research Center ( Site 0119)
    Dalton, Georgia 30720, United States
  • Delta Research Partners ( Site 0160)
    Bastrop, Louisiana 71220, United States
  • Louisiana Research Center ( Site 0161)
    Shreveport, Louisiana 71105, United States
  • Woodholme Gastroenterology Associates-Woodholme Gastroenterology Associates ( Site 0130)
    Glen Burnie, Maryland 21061, United States
  • Velocity Clinical Research Rockville ( Site 0143)
    Rockville, Maryland 20854, United States
  • Huron Gastroenterology ( Site 0102)
    Ypsilanti, Michigan 48197, United States
  • The Machuca Foundation ( Site 0115)
    Las Vegas, Nevada 89101, United States
  • Excel Clinical Research, LLC ( Site 0101)
    Las Vegas, Nevada 89109, United States
  • Southwest Gastroenterology Associates ( Site 0129)
    Albuquerque, New Mexico 87109, United States
  • Coastal Research Institute - Fayetteville ( Site 0159)
    Fayetteville, North Carolina 28304, United States
  • Lucas Research, Inc ( Site 0105)
    Morehead City, North Carolina 28557, United States
  • Texas Clinical Research Institute ( Site 0126)
    Arlington, Texas 76012, United States
  • Pinnacle Clinical Research ( Site 0104)
    Austin, Texas 78757, United States
  • Pinnacle Clinical Research-Corpus Christi ( Site 0156)
    Corpus Christi, Texas 78404, United States
  • Zenos Clinical Research ( Site 0136)
    Dallas, Texas 75230, United States
  • GI Alliance Department of Research ( Site 0162)
    Fort Worth, Texas 76104, United States
  • Houston Research Institute ( Site 0172)
    Houston, Texas 77004, United States
  • Houston Research Institute ( Site 0117)
    Houston, Texas 77079, United States
  • American Research Corporation ( Site 0131)
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research-Clinical Research Coordination ( Site 0125)
    San Antonio, Texas 78229, United States
  • University of Virginia Health System ( Site 0164)
    Charlottesville, Virginia 22908, United States
  • Flinders Medical Centre-Hepatology and Liver Transplant Medicine ( Site 1202)
    Adelaide, South Australia 5042, Australia
  • St Vincent's Hospital-Gastroenterology Department ( Site 1205)
    Melbourne, Victoria 3065, Australia
  • Toronto General Hospital ( Site 0207)
    Toronto, Ontario M5G 2C4, Canada
  • Diex Recherche Quebec ( Site 0204)
    Québec, Quebec G1V 4T3, Canada
  • Fundacion Santa Fe de Bogota ( Site 0403)
    Bogotá, Cundinamarca 110111, Colombia
  • Fundación Valle del Lili ( Site 0402)
    Cali, Valle del Cauca Department 760032, Colombia
  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Pôle de Référence Hépato Gastro-entérol ( Site 0704)
    Nice, Alpes-Maritimes 06202, France
  • CHU Bordeaux Haut-Leveque-Service d'Hépato-gastroentérologie ( Site 0701)
    Pessac, Aquitaine 33600, France
  • Hôpital de la Croix Rousse-Centre de Recherche Clinique ( Site 0705)
    Lyon, Auvergne-Rhône-Alpes 69004, France
  • Hôpital Beaujon-Hépatologie ( Site 0703)
    Clichy, Hauts-de-Seine 92110, France
  • Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren-Hépato-gastroentérologie ( Site 0702)
    Limoges, Limousin 87042, France
  • Rambam Health Care Campus ( Site 0801)
    Haifa, 3109601, Israel
  • Carmel Hospital-Liver Unit ( Site 0802)
    Haifa, 3436212, Israel
  • Shaare Zedek Medical Center ( Site 0805)
    Jerusalem, 9103102, Israel
  • Maccabi Health Services - Petah Tikva ( Site 0804)
    Petah Tikva, 4925110, Israel
  • Assuta Medical Center ( Site 0806)
    Tel Aviv, 6789140, Israel
  • Shinyurigaoka General Hospital ( Site 1401)
    Kawasaki, Kanagawa 215-0026, Japan
  • Yokohama City University Hospital ( Site 1402)
    Yokohama, Kanagawa 236-0004, Japan
  • University Hospital,Kyoto Prefectural University of Medicine ( Site 1404)
    Kyoto, 602-8566, Japan
  • Osaka Metropolitan University Hospital ( Site 1403)
    Osaka, 545-8586, Japan
  • Saga University Hospital ( Site 1405)
    Saga, 849-8501, Japan
  • ISIS CLINICAL RESEARCH CENTER ( Site 0606)
    Guaynabo, 00968, Puerto Rico
  • Klinical Investigations Group-Clinical Research ( Site 0601)
    San Juan, 00909, Puerto Rico
  • Hospital Universitario Marqués de Valdecilla-Gastroenterology and Hepatology ( Site 1004)
    Santander, Cantabria 39005, Spain
  • Hospital Clínico Universitario de Valladolid-Servicio de Endocrinologia y Nutricion ( Site 1008)
    Valladolid, Castille and León 47010, Spain
  • Hospital General de Tomelloso-Aparato Digestivo ( Site 1006)
    Tomelloso, Ciudad Real 13700, Spain
  • CHUAC-Complejo Hospitalario Universitario A Coruña-Endocrinología ( Site 1007)
    A Coruña, La Coruna 15006, Spain
  • CHUS - Hospital Clinico Universitario ( Site 1011)
    Santiago de Compostela, La Coruna 15706, Spain
  • Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 1002)
    Barcelona, 08035, Spain
  • Hospital Universitario La Paz-HEPATOLOGIA ( Site 1005)
    Madrid, 28046, Spain
  • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Unidad de Ensayos clinicos de Aparato Digestivo ( Site 1001)
    Seville, 41013, Spain
  • Chulalongkorn University ( Site 1301)
    Bangkok, Bangkok 10330, Thailand
  • Faculty of Medicine Siriraj Hospital-Department of Medicine ( Site 1302)
    Bangkok, Bangkok 10700, Thailand
  • King's College Hospital ( Site 1104)
    London, London, City of SE5 9RL, United Kingdom
  • Aberdeen Royal Infirmary-Department of Gastroenterology ( Site 1102)
    Aberdeen, Scotland AB25 2ZN, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2024 to primary completion in Aug 2026, 24 months.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 24 months is close to that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 18, 2024
StartActual
Jul 12, 2024
Primary completionActual
Aug 3, 2026
CompletionActual
Aug 3, 2026
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06465186
Responsible party
Sponsor
First posted
Jun 18, 2024
Start date
Jul 12, 2024
Primary completion
Aug 3, 2026
Completion
Aug 3, 2026
Last update
Sep 21, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion